logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
M

Mark A. Socinski

AdventHealth Cancer Institute

84H-index
782Paper Count
3.6WCitation Count
Published Papers 142
Publication Date
logo
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial
errNature Medicine
IF50
err2026-03-27
err0
errOAAI
errByoung Chul Cho; Rama Balaraman; Hua-Jun Chen; Xinmin Yu; Adewale Fawole; Zhi-gang Liu; Jiliang Zhang; Long Wu; Bin Yang; Jennifer L. Leddon; John Hamm; Yanjing Huang; Lin Wu; Pinhua Pan; Preet Singh; Andrew Beardsley; Fadi Kayali; Ardalan Davarifar; Ki Hyeong Lee; Keon-Uk Park; Youngjoo Lee; Luchun Li; Xicheng Wang; Meili Sun; Yan Yu; Vikram Jain; Svetlana Shpyro; Qiong Wang; Michael Wenger; Uğur Şahin; Sergey Efuni; Shiling Song; Kun He; Pan Zheng; Yang Liu; Kai He; Tianhong Li; Mark A. Socinski; Yi-Long Wu
errShare
errSave
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
errNature Communications
IF15.7
err2025-12-03
err0
errOAAI
errTianshi Lu; Habib Hamidi; Mark A. Socinski; Martin Reck; Federico Cappuzzo; Fabrice Barlesi; Robert M. Jotte; Sören Müller; Aditi Qamra; Assaf Amitai; Xiangnan Guan; Eloisa Fuentes; Hartmut Koeppen; Jennifer M. Giltnane; David S. Shames; Marcus Ballinger; Meng Xiao He; Yulei Wang; Minu K. Srivastava; Barzin Y. Nabet
errShare
errSave
In Reply
errONCOLOGIST
IF4.2
err2025-09-01
err0
PREAI
errPenault-Llorca, Frederique; Socinski, Mark A.
errShare
errSave
Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials
errJournal of Thoracic Oncology
IF20.8
err2025-08-05
err0
PREAI
errRoy S. Herbst; Hen Prizant; Daniel Ruderman; Jake Conway; John Shamshoian; Hartmut Koeppen; Wei Zou; Filippo de Marinis; Giuseppe Giaccone; Jacek Jassem; David R. Spigel; Mark A. Socinski; Martin Reck; Luciana Molinero; Marcus Ballinger; David Shames; Michael Griffin; Limin Yu; Nishant Agrawal; Andrew Beck; Ilan Wapinski; Stephanie Hennek; Jennifer Giltnane; Minu K. Srivastava
errShare
errSave
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)
errEXPERT REVIEW OF ANTICANCER THERAPY
IF2.8
err2025-04-17
err0
PREAI
errRaez, Luis E.; Baca, Yasmine; Ribeiro, Jennifer R.; Nieva, Jorge J.; Mamdani, Hirva; Lopes, Gilberto; Borghaei, Hossein; Socinski, Mark; Wozniak, Antoinette J.; Vanderwalde, Ari; Uribe, Carlos Carracedo; Sumarriva, Daniel; Khan, Hina; Liu, Stephen V.; Nagasaka, Misako
errShare
errSave
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy
errCLINICAL LUNG CANCER
IF3.3
err2025-01-01
err0
errOAAI
errFortman, Dylan; Wang, Hong; Vanderweele, Robert; Evans, Terry; Herman, James G.; Rhee, John; Reyes, Vincent; Mclaughlin, Brian; Wozniak, Antoinette; Somasundaram, Ashwin; Mekhail, Tarek; Socinski, Mark A.; Schulze, Katja; Villaruz, Liza C.
errShare
errSave
Correlation of safety and efficacy of atezolizumab therapy across indications
errJOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
err2024-11-12
err0
errOAAI
errDuran-Pacheco, Gonzalo; Chandler, G. Scott; Maiya, Vidya; Socinski, Mark A.; Sonpavde, Guru; Puente, Javier; Essioux, Laurent; Carter, Corey; Cardona, Jose Vicente; Mohindra, Rajat; Naidoo, Jarushka
errShare
errSave
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations
errESMO OPEN
IF8.3
err2024-04-01
err14
errOAAI
errRodon, J.; Rodriguez, E.; Maitland, M. L.; Tsai, F. y. -c.; Socinski, M. A.; Berlin, J. D.; Thomas, J. S.; Al Baghdadi, T.; Wang, I. -m.; Guo, C.; Golmakani, M.; Clark, L. N.; Gazdoiu, M.; Li, M.; Tolcher, A. W.
errShare
errSave
A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials
errBMC CANCER
IF3.4
err2024-03-25
err0
errOAAI
errLi, Lee X.; Socinski, Mark A.; Kichenadasse, Ganessan; Karapetis, Christos S.; Shahnam, Adel; Mckinnon, Ross A.; Rowland, Andrew; Hopkins, Ashley M.; Sorich, Michael J.
errShare
errSave
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2
errECLINICALMEDICINE
IF10
err2023-12-01
err2
errOAAI
errShaverdashvili, Khvaramze; Reyes, Vincent; Wang, Hong; Mehta, Dhaval; Marsh, Christopher; Waas, John K.; Vanderweele, Robert A.; Peracha, Sajid M.; Liang, Hongmei; Socinski, Mark A.; Gerber, David E.; Dowell, Jonathan E.; Villaruz, Liza C.
errShare
errSave
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
errCLINICAL LUNG CANCER
IF3.3
err2023-11-01
err0
PREAI
errBodor, J. Nicholas; Patel, Jyoti D.; Wakelee, Heather A.; Levy, Benjamin P.; Borghaei, Hossein; Pellini, Bruna; Costello, Michael R.; Dowell, Jonathan E.; Finley, Gene; Huang, Chao H.; Neal, Joel W.; Nieva, Jorge J.; Puri, Sonam; Socinski, Mark A.; Thomas, Christian; Ross, Eric A.; Litwin, Samuel; Clapper, Margie L.; Treat, Joseph
errShare
errSave
Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
errANNALS OF ONCOLOGY
IF65.4
err2023-10-01
err0
PREAI
errLe, X.; Robichaux, J. P.; Nilsson, M. B.; Ramaswamy, V.; Ravichandran, A.; Wu, J.; Elamin, Y. Y.; Hong, L.; Udagawa, H.; Socinski, M.; Bhat, G.; Lebel, F.; Vincent, S.; Bunn, V.; Su, Z.; Lawson, J.; Cross, J.; Heymach, J.
errShare
errSave
Correlation of safety and efficacy in atezolizumab therapy across indications
errANNALS OF ONCOLOGY
IF65.4
err2023-10-01
err1
PREAI
errNaidoo, J.; Duran-Pacheco, G.; Maiya, V.; Socinski, M.; Sonpavde, G. P.; Puente, J.; Essioux, L.; Carter, C. A.; Cardona, J. V.; Mohindra, R.; Chandler, S. G.
errShare
errSave
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer
errFRONTIERS IN ONCOLOGY
IF3.3
err2023-08-28
err1
errOAAI
errHsu, Robert; Chen, Denaly; Xia, Bing; Feldman, Rebecca; Cozen, Wendy; Raez, Luis E.; Borghaei, Hossein; Kim, Chul; Nagasaka, Misako; Mamdani, Hirva; Vanderwalde, Ari M.; Lopes, Gilberto; Socinski, Mark A.; Wozniak, Antoinette J.; Spira, Alexander I.; Liu, Stephen V.; Nieva, Jorge J.
errShare
errSave
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
errNATURE MEDICINE
IF50
err2023-03-16
err48
errOAAI
errAssaf, Zoe June F.; Zou, Wei; Fine, Alexander D.; Socinski, Mark A.; Young, Amanda; Lipson, Doron; Freidin, Jonathan F.; Kennedy, Mark; Polisecki, Eliana; Nishio, Makoto; Fabrizio, David; Oxnard, Geoffrey R.; Cummings, Craig; Rode, Anja; Reck, Martin; Patil, Namrata S.; Lee, Mark; Shames, David S.; Schulze, Katja
errShare
errSave
Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine
errFRONTIERS IN ONCOLOGY
IF3.3
err2023-02-01
err16
errOAAI
errVillaruz, Liza C.; Socinski, Mark A.; Weiss, Jared
errShare
errSave
A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors
errJOURNAL OF IMMUNOTHERAPY
IF2.9
err2022-09-05
err11
errOAAI
errGuo, Mengni; Liu, Jieying; Miao, Ruoyu; Ahmed, Zohaib; Yu, James; Guan, Jian; Ahmad, Sarfraz; Zhou, Shuntai; Grove, Angela; Manoucheri, Manoucher; Socinski, Mark A.; Mekhail, Tarek
errShare
errSave
The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework
errFRONTIERS IN ONCOLOGY
IF3.3
err2022-06-10
err4
errOAAI
errLiu, Stephen, V; Nagasaka, Misako; Stefaniak, Victoria; Gruver, Kristi; Lin, Yong; Ferry, David; Socinski, Mark A.; Zhang, Li
errShare
errSave
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer
errEXPERT OPINION ON INVESTIGATIONAL DRUGS
IF4.1
err2022-06-03
err6
errOAAI
errCho, Byoung Chul; Goldberg, Sarah B.; Kim, Dong-Wan; Socinski, Mark A.; Burns, Timothy F.; Lwin, Zarnie; Pathan, Nuzhat; Ma, Wei Dong; Masters, Joanna C.; Cossons, Nandini; Wilner, Keith; Nishio, Makoto; Husain, Hatim
errShare
errSave
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
errNATURE MEDICINE
IF50
err2022-04-14
err95
errOAAI
errKim, Edward S.; Velcheti, Vamsidhar; Mekhail, Tarek; Yun, Cindy; Shagan, Sarah M.; Hu, Sylvia; Chaes, Young Kwang; Leal, Ticiana A.; Dowell, Jonathan E.; Tsai, Michaela L.; Dakhil, Christopher S. R.; Stella, Philip; Jin, Yanling; Shames, David S.; Schleifman, Erica; Fabrizio, David A.; Phan, See; Socinski, Mark A.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
C
Charles M. Perou
H-index: 193 · Papers: 2.0K
J
John D. Minna
H-index: 174 · Papers: 2.3K
M
Mark G. Kris
H-index: 149 · Papers: 1.4K
Y
Yi‐Long Wu
H-index: 135 · Papers: 2.2K
T
Tony Mok
H-index: 131 · Papers: 1.1K
View more